Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Pharmaceutical Technology

NOVEMBER 22, 2022

The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry. billion towards the “pandemic-busting plan”, which involves the investigation of rapid response vaccine technologies. The UK Government is behind this effort.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

XTalks

AUGUST 26, 2020

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

pharmaphorum

APRIL 28, 2021

“Text mining was also able to highlight new insights into the mechanisms of pancreatic cancer’s immune evasion, which refers to cancer cells’ ability to evade an immune response” . Figure 1: Trending ‘Protein and Genomic’ terms with a semantic relationship to pancreatic cancer. About the author.

Immune Response 105

Immune Response Life Science Genomics Genome 105

XTalks

NOVEMBER 6, 2020

Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

OCTOBER 11, 2024

The vaccine uses recombinant RSV glycoprotein F, stabilized in its prefusion conformation (RSVPreF3), along with GSK’s AS01E adjuvant to boost the immune response — the same adjuvant used in Shingrix, its shingles vaccine, but at a lower dose.

Vaccine 103

Vaccine Vaccination Immune Response Trials 103

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine 96

Vaccine Vaccination Protein Manufacturing 96

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial. At six months, 29.5

Vaccine 105

Vaccine Vaccination Immune Response Trials 105

XTalks

JULY 2, 2021

Conspiracy theories citing similarities between a placental protein called syncytin-1 and the spike protein of the coronavirus started doing the rounds last year, claiming that vaccines based on this spike protein could cause the immune system to attack the placenta and lead to pregnancy issues.

Vaccine 105

Vaccine Vaccination Protein Immune Response 105

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. These strains of the virus were recommended by the World Health Organization (WHO).

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Clinical Trial Results.

Vaccine 59

Vaccine Vaccination Immune Response Protein 59

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins. The F-protein facilitates the fusion of the virus with the membrane of the host cell.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

Pharmaceutical Technology

JULY 22, 2022

Peter Hotez’s tweet on PAI Life Sciences’ phase 1 trial of its snail fever vaccine. The phase 1 clinical trial will evaluate the safety and immune response of the vaccine in healthy individuals at the Kaiser Permanente Washington Health Research Institute in Seattle, the article detailed. Retweets: 113.

Vaccine 130

Vaccine Vaccination Life Science Immune Response 130

XTalks

DECEMBER 29, 2023

Classified as a bispecific T-cell engager (BiTE molecule), tarlatamab consists of two essential parts: one binds to T-cells, vital in immune response, and the other targets cancer cells. Tarlatamab differs from conventional chemotherapy as it’s an immunotherapy designed to help immune cells detect, attach to and fight cancer cells.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

FEBRUARY 19, 2024

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. Paduano Professor in Pediatrics at Weill Cornell Medicine, in a news release.

Vaccine 59

Vaccine Vaccination Trials Clinical Trials 59

XTalks

AUGUST 14, 2023

XTALKS WEBINAR: Cancer Immunotherapy: Exploring Imaging as a Catalyst to Immune Response Prediction Live and On-Demand: Wednesday, September 27, 2023, at 2pm EDT (11am PDT) Register for this free webinar to discover the present and transformative impact of predictive biomarkers on immunotherapy response.

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

pharmaphorum

MARCH 23, 2021

The VDC platform takes the form of a virus-like particle (VLPs) that bind selectively to proteins that are found on the surface of tumour cells but not on normal, healthy cells, which are joined to drug molecules that enhance their cancer-killing activity. The post Aura raises $80m to develop its virus-like cancer drugs appeared first on.

Development 71

Development Drugs Immune Response Life Science 71

XTalks

OCTOBER 25, 2022

Imjudo is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody that blocks the action of CTLA-4. Inhibition of the protein aids in T-cell activation to prime the immune system against cancer cells to induce their death.

FDA Approval 98

FDA Approval Trials Drugs Immune Response 98

XTalks

MAY 19, 2021

In a small study conducted by researchers from the University of California and the Gladstone Institute of Virology in San Francisco, it was found that both vaccines elicited immune responses, particularly robust T cell responses, against the UK B.1.117 1.117 and South African B.1.351 1.351 variants. 1.117 and B.1351

Vaccine 82

Vaccine Vaccination Protein Immune Response 82

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

XTalks

APRIL 7, 2021

The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immune response to SARS-CoV-2. The test involves self-collection of a fingerstick dried blood sample. percent of the time, and negative results agreeing 100 percent of the time.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

MARCH 2, 2021

It is based on the insertion of a portion of the gene coding for the spike protein of SARS-CoV-2 into a replication-inactive adenovirus-associated virus (AAV). The AAV serves as a vector to carry the gene into cells from which the spike protein fragment is made to elicit an immune response.

Vaccine 98

Vaccine Vaccination Trials Clinical Trials 98

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccine 97

Vaccine Vaccination Clinical Trials Clinical Trials 97

XTalks

SEPTEMBER 15, 2020

The vaccine triggers an immune response against pro-inflammatory processes resulting from autoimmune attack of the pancreas – the inflammation helps to destroy the insulin-producing ?-islet Specifically, the vaccine contains human recombinant glutamate decarboxylase 65 (GAD65) protein conjugated to aluminum hydroxide (GAD-alum).

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

JANUARY 11, 2023

It also seems to be very adept at evading the immune response owing to a plethora of mutations that makes it immune evasive. “It From the other parent strain, it received a separate set of mutations that made it more immune evasive. In the northeast of the country, XBB.1.5

Scientist 98

Scientist Vaccine Vaccination Genetics 98

XTalks

OCTOBER 1, 2024

mRNA therapies work by instructing cells to produce specific proteins that can enhance the body’s natural defenses or correct deficiencies. In the context of asthma, this means potentially restoring the immune response in the respiratory tract to better protect against viral infections that often trigger severe asthma symptoms.

Development 52

Development Drugs Immune Response Protein 52

XTalks

MAY 4, 2023

Celiac disease is an autoimmune disorder that is triggered by the consumption of gluten, a protein found in barley, wheat and rye. When a person with celiac disease eats something that contains gluten, their immune system attacks their small intestine, damaging the lining and interfering with the absorption of nutrients from food.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

XTalks

MAY 1, 2023

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. Reduction in these two biomarkers in response to tofersen is believed to predict clinical benefit for patients. How Does Qalsody Work?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

XTalks

JUNE 18, 2021

s (NASDAQ: REGN ) antibody therapy REGEN-COV consists of a cocktail of two virus-neutralizing monoclonal antibodies, casirivimab and imdevimab, which bind non-competitively to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Cytiva , a global life sciences leader, is supporting Clover Biopharmaceuticals , a global clinical-stage biotechnology company, to help accelerate the development and manufacturing of a protein-based S-Trimer subunit vaccine candidate. SHANGHAI , Nov. About Cytiva.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

XTalks

MARCH 10, 2021

Adaptive Biotechnologies’ T-Detect COVID Test is a next-generation sequencing (NGS) test that can indicate recent or prior infection with SARS-CoV-2 through detection of a T cell immune response to the virus. This is the first T cell test of its kind for the detection of COVID-19 infection.

Protein 98

Protein RNA Antibody Production 98

XTalks

NOVEMBER 10, 2020

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. These are very promising results. Plant-Based Vaccine Technology.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52